Biosign appoints new Chief Financial Officer and schedules Investor Conference Call

Biosign appoints new Chief Financial Officer and schedules Investor Conference 
Call 
/NOT FOR DISTRIBUTION IN THE UNITED STATES OR THROUGH UNITED STATES WIRE 
SERVICES/ 
TORONTO, Jan. 6, 2014 /CNW/ - Biosign Technologies Inc. (TSXV: BIO) ("Biosign" 
or the "Company") is pleased to announce the appointment of Mr. Mario 
Laflamme, CA, CPA as Chief Financial Officer, to replace Mr. William Randolph 
(Randy) Polley, CA who will remain with the Company as a senior business 
development executive. 
Mr. Laflamme will oversee Biosign's finance and accounting functions, 
utilizing extensive financial management and corporate development experience 
gained through working with rapidly growing firms in the technology sector in 
both the United States and Canada. He most recently served as CFO for LED 
Roadway Lighting, a Halifax, Nova Scotia based outdoor lighting technology 
company; as Managing Director of Mass Tech Partners, a Massachusetts based 
business and financial management firm; and as President & CFO of Univisions 
Crimson Group, a corporate Audio/Video services firm formed by the merger of 
Univisions and Crimson Tech, and sold to York Telecom. Notably, Mr. Laflamme 
was Vice President, Finance and Vice President, Operations for The Learning 
Company, (formerly SoftKey Software), a Canadian company that grew through 
acquisitions to over $800 million in revenue and was later acquired by Mattel 
Inc. 
The Company wishes to thank Mr. Polley for his service as CFO. He has helped 
guide Biosign through our intense restructuring period, and his dedication, 
skill and professionalism are greatly appreciated. We are pleased that he has 
agreed to continue working with us as a key executive in the areas of business 
development and sales. 
Biosign's CEO Mr. Robert Kaul stated, "We are very pleased to welcome Mr. 
Laflamme to Biosign as our new CFO. He brings us specific experience working 
with fast growing companies in both Canada and the United States, which we 
will need as we move forward with our previously articulated plan to grow by 
acquisition in 2014 and beyond. Furthermore, as Biosign increasingly commits 
to doing business in Atlantic Canada, Mr. Laflamme's location in Halifax will 
be a benefit as we engage more deeply with government and industry 
stakeholders in that region." 
INVESTOR CONFERENCE CALL JANUARY 9, 2014 
Biosign is pleased to announce an Investor Conference Call, scheduled for 
Thursday, January 9(th), 2014 at 11:00 AM Eastern Daylight Time. During this 
call, Biosign CEO Robert Kaul will read a prepared statement commenting on 
recent news releases and providing additional discussion on the Company's 
business plan. 
To participate in the call, please use the following login credentials: 
Dial-In Number: Local: (718) 514-2085, Toll Free: 1-877-394-5901 
No PIN number is required. Participants can dial Star 1 (*1) to ask a question 
during the call - a live operator will be moderating. 
In particular, Mr. Kaul will comment on the following announcements:
- "Biosign licenses award-winning applepeak source code" November 18, 2013
- "Biosign repatriates exclusive rights for Middle East and Asia" November 25, 
2013
- "Biosign and RJL Systems announce co-marketing agreement" December 23, 2013
- "Biosign invests in HR infrastructure company" December 24, 2013
- "Biosign announces $6.0 million software and services sale" December 27, 2013
- "Biosign acquires IBL Internet Business Logic Inc" December 31, 2013
Plus any additional releases issued prior to the date of the conference call. 
Following the presentation, Mr. Kaul will answer a number of questions 
submitted from participants regarding the business of the Company. The 
conference call is open to any investor or stakeholder, including 
shareholders, broker-dealers and other securities professionals. The call will 
be recorded and available for review at http://biosign.com/investors. 
To submit one or more questions to the CEO, please email your question to 
ceo@biosign.com with the words "Investor Question for Conference Call" in the 
subject line. Biosign management will endeavour to address as many questions 
as possible in the one-hour time period allocated to the call. 
Biosign CEO Robert Kaul stated, "Biosign has recently made a number of 
material announcements related to our business plan. Management is pleased to 
be able to communicate with investors and other interested parties in order to 
place these announcements into greater context, and to address various 
stakeholder inquiries." 
About Biosign Technologies Inc. 
Biosign Technologies Inc. (TSXV: BIO) provides automated, software enabled 
health information solutions including the Pulsewave(®) Health Monitor and 
the Healthanywhere™ Patient monitoring / self-management platform. The 
Company's Pulsewave(®) Health Monitor solution enables pulse wave data 
collection for cardiovascular clinical decision support and self-care, while 
its Healthanywhere™ solution offers industry-leading remote patient 
monitoring and patient centred care management. The Company also offers a 
number of cardiovascular screening programs for consumers under its Heart 
Friendly™ brand, including Heart Friendly™ Practice, Heart Friendly™ 
Dentist, and Heart Friendly™ Fitness. For more information on Biosign, 
please visit www.biosign.com 
Forward-Looking Statements 
This release contains forward-looking statements. Forward-looking statements, 
without limitation, may contain the words believes, expects, anticipates, 
estimates, intends, plans, or similar expressions. Forward-looking statements 
are not guarantees of future performance. They involve risks, uncertainties 
and assumptions and Biosign's actual results could differ materially from 
those anticipated. Forward looking statements are based on the opinions and 
estimates of management at the date the statements are made, and are subject 
to a variety of risks and uncertainties and other factors that could cause 
actual events or results to differ materially from those projected in the 
forward-looking statements. In the context of any forward-looking information 
please refer to risk factors detailed in, as well as other information 
contained in the company's filings with Canadian securities regulators 
(www.sedar.com). 
Neither TSX Venture Exchange nor its Regulation Services Provider (as that 
term is defined in policies of the TSX Venture Exchange) accepts 
responsibility for the adequacy or accuracy of this release.
 

SOURCE  Biosign Technologies Inc. 
Biosign Contact Information: 
Robert Kaul Chief Executive Officer Biosign Technologies Phone: (416) 218-9800 
ext. 201 Email:ceo@biosign.com 
To view this news release in HTML formatting, please use the following URL: 
http://www.newswire.ca/en/releases/archive/January2014/06/c7290.html 
CO: Biosign Technologies Inc.
ST: Ontario
NI: HEA CONF 2575 WNEWS ERN  
-0- Jan/06/2014 21:01 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.